Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2091
Full metadata record
DC FieldValueLanguage
dc.contributorKelly, R.en_US
dc.contributorWong, S.en_US
dc.contributorShapiro, J.en_US
dc.contributorWeickhardt, A.en_US
dc.contributorParente, P.en_US
dc.contributorAzad, A.en_US
dc.contributorBrown, Stephenen_US
dc.contributorTran, B.en_US
dc.date.accessioned2023-02-06T23:02:31Z-
dc.date.available2023-02-06T23:02:31Z-
dc.date.issued2022-
dc.identifier.govdoc02039en_US
dc.identifier.urihttp://hdl.handle.net/11054/2091-
dc.description.abstractBackground: The addition of docetaxel to androgen deprivation therapy (ADT) for metastatic hormone sensitive prostate cancer (mHSPC) has demonstrated significant overall survival (OS) benefit. We aimed to evaluate the real-world utilisation rates of upfront docetaxel and associated patient outcomes in Australia. Annals of Oncology abstracts S1498 Volume 33 - Issue S9 - 2022 Methods: The electronic CRPC Australian Database (ePAD) was interrogated to identify patients diagnosed with mHSPC between July 2015 and July 2021. Clinicopathological features, treatment and outcome data, stratified by treatment with upfront docetaxel, were analysed through descriptive statistics. Survival analyses were calculated using the Kaplan-Meier method and groups compared using log-rank tests. Results: We identified 324 mHSPC patients with median age 69.8 years and median follow up 32.6 months. 152 (47%) received upfront docetaxel. 129 patients (85%) completed 6 cycles of docetaxel. Rates of docetaxel use were stable across a 6-year period (48% in 2015, 50% in 2021). Patients treated with docetaxel were significantly younger (mean 66 vs 74 years, p¼en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2023-02-06T04:34:01Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2023-02-06T23:02:31Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2023-02-06T23:02:31Z (GMT). No. of bitstreams: 0 Previous issue date: 2022en
dc.titleReal-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer.en_US
dc.typeConferenceen_US
dc.type.specifiedPresentationen_US
dc.bibliographicCitation.conferencedateDecember 2-4en_US
dc.bibliographicCitation.conferencenameESMO Asia Congress 2022en_US
dc.bibliographicCitation.conferenceplaceSingaporeen_US
dc.subject.healththesaurusPROSTATE CANCERen_US
dc.subject.healththesaurusHORMONE THERAPYen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.